EP0523037A4 - Fluid resuscitation - Google Patents
Fluid resuscitationInfo
- Publication number
- EP0523037A4 EP0523037A4 EP19900907852 EP90907852A EP0523037A4 EP 0523037 A4 EP0523037 A4 EP 0523037A4 EP 19900907852 EP19900907852 EP 19900907852 EP 90907852 A EP90907852 A EP 90907852A EP 0523037 A4 EP0523037 A4 EP 0523037A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- biopolymer
- dfo
- fluid resuscitation
- deferoxamine
- dpo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
Definitions
- the present invention relates to fluid resuscitation.
- Such resuscitation is required or is desirable in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke derived frcm combustion, and hei ⁇ iorrhagic shock.
- Burn injury is often acco ⁇ panied by injury to the lungs caused by inhalation of hot and/or toxic substances, such as snroke, derived from combustion.
- the critical period of initial resuscitation i.e. when fluid is administered, is the time when reperfusion injury occurs. During this period, which may be as short as a minute or as long as several hours, oxygen radical mediated injury appears to occur.
- ej ⁇ anders crystalloids and colloids
- Deferoxamine or desferrioxamine
- Deferoxamine mesylate is commercially available and is used to treat severe iron intoxication, iron storage disease or iron overload resulting from hemolysis due to drugs, thalassemia, sickle-cell anemia, frequent blood transfusions and the like.
- deferoxamine mesylate There are a number of problems with the clinical use of deferoxamine mesylate. Since the drug is not appreciably absorbed when orally administered, it generally must be given parenterally. Once administered, the drug is very rapidly excreted. For example, in humans the drug exhibits a vascular half-life of only about 5-10 min. Chelation therapy with the drug, as a result, involves continuous infusion or frequent intramuscular injections, which may cause pain and/or induration at the injection site. Further, the acute and chronic toxicities of deferoxamine are relatively high, making the substance less versatile for therapeutic uses.
- DFO deferoxamine
- DES diethylstilbesterol
- EP-0 304 183A discloses pharmaceutically acceptable water-soluble biopolymers covalently bonded to deferoxamine. Such biopolymers covalently bonded to deferoxamine are herein referred to as conjugates.
- Preferred conjugates consist of pharmaceutically acceptable water-soluble polysaccharides covalently bonded to deferoxamine, pharmaceutically acceptable water-soluble proteins covalently bonded to deferoxamine and water-soluble inulm-deferoxamine adducts. It has now been discovered that such conjugates of deferoxamine are useful in fluid resuscitation.
- the present invention relates to the use of a pharmaceutically acceptable water-soluble biopolymer and deferoxamine (DFO) for use in fluid resuscitation.
- DFO deferoxamine
- the invention relates to the use of such biopolymer and DFO for the preparation or manufacture of a medicament for use in fluid resuscitation.
- the biopolymer may be covalently bonded to the DFO. Conjugation of DFO as described above decreases the toxicity of the DFO whilst not reducing or not proportionally reducing its chelating ability.
- the biopolymer may be a polysaccharide or a protein.
- the DPO may be covalently bonded directly to aldehydde groups on the polysaccharide.
- the DFO may be covalently bonded directly to one or more amino, carboxyl or thiol groups on the protein.
- the polysaccharide may comprise dextran, hyaluronic acid, inulin, starch, e.g. hydroxyethyl starch or other modified form of starch.
- the protein may co ⁇ prise serum albumin or other plasma protein fraction (human or animal) or hemoglobin.
- hemoglobin may be used in resuscitation fluids. Such fluids will provide oxygen to ischemic tissue but may be toxic due to release of iron from the iron-containing protein. The presence of DPO, either bound to or mixed with the hemoglobin may decrease such toxicity.
- the DFO-conjugate may be prepared by method as described in EP-E- 0 304 183A.
- DPO and the biopolymer, whether or not conjugated together are preferably formulated as an aqueous solution suitable for parenteral administration e.g. by intramuscular, intraperitoneal or intravenous infusion.
- the conjugates between, and the simple mixtures of, polysaccharides and DPO preferably contain from 5 to 25% chelator by weight. It is preferred that -solutions having conjugate cor ⁇ _ * entrations between 2 and 10% (w/v) , dissolved in saline or lactated Ringer's solution, are used for fluid resuscitation. Effective doses are generally in the range of from approximately 20 to 300 mg chelator/kg body weight, although higher doses of conjugated DPO can be given in certain circumstances, for example in the treatment of acute iron poisoning. Care should be taken when administering the chelator in a form not conjugated to the colloid, since adverse reactions can occur even at moderate doses. - 4A -
- Fluid resuscitation using the biopolymer and the DPO ameliorates systemic oxidant injury occurring during ischemia and subsequent reperf sion.
- the fluid resuscitation may be indicated in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke, derived from combustion, - hemorrhagic shock and other types of trauma.
- Oxygen derived radicals such as the hydroxyl radical
- Oxygen derived radicals are cytotoxic and highly reactive molecules are thought to contribute to cellular death in hemorrhagic and thermal shock.
- Production of hydroxyl radical is catalyzed by transition metal ions.
- Chelation of transition metal ions with DPO prevents formation of hydroxyl radicals.
- the burn was produced under halothane nitrous anesthesia.
- the burn involved bilateral prefemoral areas over the distribution of bilateral flanks. Resuscitation was begun immediately post burn. The animals were then monitored for 6 hours, then sacrificed. Three groups of animals were studied.
- Group 1 Ringers alone as resuscitation fluid Group 2 5% hydroxyethyl starch alone as resuscitation fluid; Group 3 5% deferoxamine chelator attached i.e. (covalently bonded) to hydroxyethyl starch alone as recuscitation fluid.
- Aortic, . central venous, pulmonary arterial, and pulmonary wedge pressures as well as cardiac output were recorded. Hourly values for arterial and venous blood gases as well as ' co-oximetry were measured. Co-oximetry measurements include total hemoglobin, reduced hemoglobin, oxygen content, oxygen saturation, and oxygen capacity. Dynamic and static lung compliance was also measured. Urine output and specific gravity were recorded.
- Malondialdehyde (MDA), a measure of lipid peroxidation, was measured in both lung and liver tissue.
- Group 3 receiving iron chelator atached to hydroxyethyl starch, required significantly less fluid to maintain hemodynamic stability than either of the other two groups.
- n number of sheep in group.
- a porcine hemorrhagic shock model was used to evaluate the effects of 3 resuscitative fluids on survival and hepatic function. Fasted swine (14-16 kg) underwent splenectomy and placement cf arterial - 8 -
- PS pentastarch (a form of hydroxyethyl starch)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to fluid resuscitation of the human or animal body by administration of deferoxamine (DFO) and a water-soluble biopolymer. The DFO and the biopolymer are preferably bonded together. The biopolymer may be a polysaccharide or a protein. The DFO and the biopolymer are preferably formulated as an aqueous solution suitable for oral administration. The fluid resuscitation may be effected for ameliorating systemic oxidant injury occuring during ischemia and subsequent reperfusion. The fluid resuscitation may be indicated in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke derived from combustion, hemorrhagic shock and other types of trauma.
Description
FLUID RESUSCITATION
Field of the Invention
The present invention relates to fluid resuscitation. Such resuscitation is required or is desirable in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke derived frcm combustion, and heiτiorrhagic shock.
Background of the Invention
Thermal injury and severe bleeding lead to shock. The acute therapeutic intervention is similar in both situations: primary treatment is fluid therapy. In the case of hemorrhagic shock, the lost blood volume must be replaced as quickly as possible. Initially lost blood volume is provided either by salt solutions, so called crystalloids, or with colloids, such as dextran or hydroxyethyl starch. If blood is available, the physician will replace lost blood by transfusion.
Burn injury is often accoπpanied by injury to the lungs caused by inhalation of hot and/or toxic substances, such as snroke, derived from combustion.
Severe burn injury affecting more than 15-20% of the total body area leads to tremendous loss of fluid through the burned skin and fluid replacement is an extremely important form of therapy for these patients. Both crystalloids and colloids are routinely used. Lung injury caused by smoke inhalation and other toxic fumes is also treated with fluids since the injury to the lung also causes loss of fluid.
The critical period of initial resuscitation, i.e. when fluid is administered, is the time when reperfusion injury occurs. During this period, which may be as short as a minute or as long as several hours, oxygen radical mediated injury appears to occur.
Presently used volume ejφanders (crystalloids and colloids) do not provide the anti-oxidant properties necessary to mitigate such injury.
Deferoxamine (or desferrioxamine) and its pharmaceutically- acceptable salts are chelating agents. Deferoxamine mesylate is commercially available and is used to treat severe iron intoxication, iron storage disease or iron overload resulting from hemolysis due to drugs, thalassemia, sickle-cell anemia, frequent blood transfusions and the like.
There are a number of problems with the clinical use of deferoxamine mesylate. Since the drug is not appreciably absorbed when orally administered, it generally must be given parenterally. Once administered, the drug is very rapidly excreted. For example, in humans the drug exhibits a vascular half-life of only about 5-10 min. Chelation therapy with the drug, as a result, involves continuous infusion or frequent intramuscular injections, which may cause pain and/or induration at the injection site. Further, the acute and chronic toxicities of deferoxamine are relatively high, making the substance less versatile for therapeutic uses.
The substance deferoxamine is often abbreviated DFO or DES (not to be confused with diethylstilbesterol) . For consistency, only the abbreviation DFO will be used herein. Terms such as "Dextran-DPO" mean an adduct of the polymer (dextran) with DFO. Such an adduct may include more than one DFO moiety per unit substrate.
EP-0 304 183A (corresponding to U.S. patent no. 4 863 964) discloses pharmaceutically acceptable water-soluble biopolymers covalently bonded to deferoxamine. Such biopolymers covalently bonded to deferoxamine are herein referred to as conjugates. Preferred conjugates consist of pharmaceutically acceptable water-soluble polysaccharides covalently bonded to deferoxamine, pharmaceutically acceptable water-soluble proteins covalently bonded to deferoxamine and water-soluble inulm-deferoxamine adducts.
It has now been discovered that such conjugates of deferoxamine are useful in fluid resuscitation.
It has also been discovered that DPO and water-soluble biopolymers even if not covalently bonded together may be useful in fluid resuscitation.
Summary of the Invention
The present invention relates to the use of a pharmaceutically acceptable water-soluble biopolymer and deferoxamine (DFO) for use in fluid resuscitation.
In particular the invention relates to the use of such biopolymer and DFO for the preparation or manufacture of a medicament for use in fluid resuscitation.
The biopolymer may be covalently bonded to the DFO. Conjugation of DFO as described above decreases the toxicity of the DFO whilst not reducing or not proportionally reducing its chelating ability.
However, we have some indications that in certain circumstances, free DFO is not as toxic as co πronly asserted.
Accordingly it is within the scope of the invention to use the DFO and the biopolymer in combination with each other as described above but not covalently bound or otherwise conjugated together.
The biopolymer may be a polysaccharide or a protein.
Where the biopolymer is a polysaccharide, the DPO may be covalently bonded directly to aldehydde groups on the polysaccharide.
Where the biopolymer is a protein, the DFO may be covalently bonded directly to one or more amino, carboxyl or thiol groups on the protein.
The polysaccharide may comprise dextran, hyaluronic acid, inulin, starch, e.g. hydroxyethyl starch or other modified form of starch.
The protein may coπprise serum albumin or other plasma protein fraction (human or animal) or hemoglobin.
It is envisaged that hemoglobin may be used in resuscitation fluids. Such fluids will provide oxygen to ischemic tissue but may be toxic due to release of iron from the iron-containing protein. The presence of DPO, either bound to or mixed with the hemoglobin may decrease such toxicity.
The DFO-conjugate may be prepared by method as described in EP-E- 0 304 183A.
DPO and the biopolymer, whether or not conjugated together, are preferably formulated as an aqueous solution suitable for parenteral administration e.g. by intramuscular, intraperitoneal or intravenous infusion.
The conjugates between, and the simple mixtures of, polysaccharides and DPO preferably contain from 5 to 25% chelator by weight. It is preferred that -solutions having conjugate corκ_*entrations between 2 and 10% (w/v) , dissolved in saline or lactated Ringer's solution, are used for fluid resuscitation. Effective doses are generally in the range of from approximately 20 to 300 mg chelator/kg body weight, although higher doses of conjugated DPO can be given in certain circumstances, for example in the treatment of acute iron poisoning. Care should be taken when administering the chelator in a form not conjugated to the colloid, since adverse reactions can occur even at moderate doses.
- 4A -
Fluid resuscitation using the biopolymer and the DPO ameliorates systemic oxidant injury occurring during ischemia and subsequent reperf sion.
The fluid resuscitation may be indicated in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke, derived from combustion, - hemorrhagic shock and other types of trauma.
Oxygen derived radicals, such as the hydroxyl radical, are cytotoxic and highly reactive molecules are thought to contribute to cellular death in hemorrhagic and thermal shock. Production of hydroxyl radical is catalyzed by transition metal ions. Chelation of transition metal ions with DPO prevents formation of hydroxyl radicals.
By using the DFO and biopolymer according to the present invention
two goals are achieved. Firstly critical volume is provided and, secondly reperfusion injury is prevented or at least attenuated, by removing the iron that catalyzes the reactions leading to formation of oxygen and lipid radicals. This represents a major advance for treating shock and trauma, at the site of an accident, during transport to, and in the hospital.
The need for volume replacement following major thermal injury is less acute than in the case of hemorrhagic shock. However, large volumes are often used and the fluid therapy must be continued for several days. The events occuring in the damaged microvasculature during and following burn injury cannot be clas ified as an example of ischemia followed by reperfusion. However, it has been proposed that the "leaky" microvasculature observed following burn in the injured tissue, and the functional impairment of distal organs (heart, lung and liver), is in part due to o vgen radicals. Treatment with the DFO and biopolymer according to the present invention result, in decreased volume demand (=less leaky microvasculature) and iirproved function of distal organs (---improved cardiac output, lung function and liver blood flow).
The invention is illustrated by the following examples.
Example 1 - Treatment of burn injury
MODEL
Twentythree adult sheep, weighing 40-50kg, were studied. Sheep were prepared with chronic soft tissue lymph fistulas and vascular catheters. Vascular catheters included a swan ganz catheter, carotid arterial line, and jugular venous line. Animals were allowed to recuperate for at least 3 days after the surgical procedure.
BURN INJURY
After a 2 hour ar.es hesia baseline period, a 0-_ r.irά i- r oocy
- -
burn was produced under halothane nitrous anesthesia. The burn involved bilateral prefemoral areas over the distribution of bilateral flanks. Resuscitation was begun immediately post burn. The animals were then monitored for 6 hours, then sacrificed. Three groups of animals were studied.
Group 1 Ringers alone as resuscitation fluid; Group 2 5% hydroxyethyl starch alone as resuscitation fluid; Group 3 5% deferoxamine chelator attached i.e. (covalently bonded) to hydroxyethyl starch alone as recuscitation fluid.
PHYSIOLOGIC MEASUREMENTS
Aortic, . central venous, pulmonary arterial, and pulmonary wedge pressures as well as cardiac output were recorded. Hourly values for arterial and venous blood gases as well as' co-oximetry were measured. Co-oximetry measurements include total hemoglobin, reduced hemoglobin, oxygen content, oxygen saturation, and oxygen capacity. Dynamic and static lung compliance was also measured. Urine output and specific gravity were recorded.
BIOCHEMICAL MEASUREMENTS
Malondialdehyde (MDA), a measure of lipid peroxidation, was measured in both lung and liver tissue.
RESULTS
1) Group 3, receiving iron chelator atached to hydroxyethyl starch, required significantly less fluid to maintain hemodynamic stability than either of the other two groups.
The lipid peroxidation level of Group 2 in both lung and liver tissue was within normal levels compared to marked increases in the other groups.
- -
MDA nMol/g tissue
n = number of sheep in group.
3) Urine hemolysis seen with burn injury was abolished in Group 3.
4) In the acute-resuscitation period following burn injury (1-2 hrs), an increase in oxygen consumption was noted with the desferal colloid solution, as compared to the Ringers and colloid groups that either had a decrease or no change from controls.
These results show normal levels of lipid peroxidation and greater hemodynamic stability with less fluid volume required. Animals treated with the colloid-chelator conjugate (i.e. the DPO covalently bonded to hydroxyethyl starch) had improved perfusion and blood flow distribution as evidenced by an increase in oxygen consumption.
Example 2 - Treatment of Hemorrhagic Shock
MODEL
A porcine hemorrhagic shock model was used to evaluate the effects of 3 resuscitative fluids on survival and hepatic function. Fasted swine (14-16 kg) underwent splenectomy and placement cf arterial
- 8 -
and venous catheters.
INJURY
Awake animals were then bled at lml/kg/min to a mean pressure of 40 mmHg, maintained for 1 hour, and resuscitated over 30 rnins. with 1 of 3 fluids: LR - (n=4) at 3 ml/ml shed blood; PS/LR - 5% PS in LR (n=5) at 1 ml/ml shed blood; DFO-PS/LR- 5% PS with 7.5 mg DPO/ml (n=6) at 1 ml/ml shed blood.
RESULTS
There were no significant differences between groups in MAP, HR, CVP, T or Hct at baseline or after resuscitatiion. LR treated animals all survived less than 2.5 hrs, after resuscitation, whereas PS/LR and DFO-PS/LR survived to sacrifice at 24 hours (P 0.01). AST levels (IU/L) showed no significant difference pre-op and post-resuscitation, but were elevated for PS/LR vs. DFO-PS/LR (338 +/- 161 vs. 106 +/- 57, p 0.03. Colloid resuscitation significantly prolonged survival in this hemorrhage model. This data suggests that DPO conjugate may preserve hepatocyte or microvascular integrity in hemorrhagic shock. Animals treated with the DFO-conjugate seem to have better perfusion of injured tissue, based on hermodynamic variables, than those receiving conventional fluid resuscitation with colloid alone or crystalloid.
Abbreviations used above in this example have the following meanings:
LR lactated Ringers
PS pentastarch (a form of hydroxyethyl starch)
DFO-PS DFO/PS conjugate
AST aspartate amino transferase
Claims
1. A method of fluid resuscitation of the human or animal body, comprising adninistering deferoxamine (DPO) and a water-soluble biopolymer.
2. A method according to claim 1, wherein the DPO and biopolymer are covalently bonded together.
3. A method according to any preceding claim, wherein the biopolymer is a polysaccharide.
4. A method according to claim 3, wherein the DPO is covalently bonded directly to one or more aldehyde on the polysaccharide.
5. A method according to any of claim 3 or 4, wherein the polysaccharide is dextran, hyaluronic acid, inulin or a starch.
6. A method according to claim 1 or 2, wherein the biopolymer is a protein.
7. A method according to claim 6, wherein the DFO is covalently bonded directly to one or more amino, carboxyl or thiol groups on the protein.
8. A method according to claim 6 or 7, wherein the protein is a plasma protein fraction or hemoglobin.
9. A method according to any preceding claim, wherein the DFO and biopolymer are formulated as an aqueous solution suitable for parenteral administration.
10. A method according to any preceding claim, wherein the fluid resuscitation is effected for ameliorating systemic oxidant injury occurring during ischemia and subsequent reperfusion.
11. A method according to any preceding claim, wherein the fluid
resuscitation is coπprised in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances or heπorrhagic shock.
12. A method according to any preceding claim except claims 2, 4 and 7, wherein the DFO and the biopolymer are not covalently bound or otherwise conjugated together.
13. Use of deferoxamine .and deferoxamine (DPO) and a water-soluble biopolymer for the preparation or manufacture of a medicament for use in fluid resuscitation.
14. Use according to claim 13, wherein the DFO and biopolymer are as specified in any of claims 2 to 9 and 12.
15. Use according to claim 13 or 14, wherein the fluid resuscitation is as specified in claim 10 or 11.
16. A medicament comprising deferoxamine and a water-soluble biopolymer, for use in fluid resuscitation.
17. A medicament according to claim 16, wherein the DFO and the
0 biopolymer are as specified in any of claims 2 to 9 and 12.
18. A medicament according to claim 16 or 17, wherein the fluid resuscitation is as specified in claim 10 or 11.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002084073A CA2084073A1 (en) | 1990-03-30 | 1990-03-30 | Fluid resuscitation |
| PCT/US1990/001768 WO1991015215A1 (en) | 1990-03-30 | 1990-03-30 | Fluid resuscitation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0523037A1 EP0523037A1 (en) | 1993-01-20 |
| EP0523037A4 true EP0523037A4 (en) | 1993-07-28 |
Family
ID=25675695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19900907852 Withdrawn EP0523037A4 (en) | 1990-03-30 | 1990-03-30 | Fluid resuscitation |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP0523037A4 (en) |
| WO (1) | WO1991015215A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672334A (en) * | 1991-01-16 | 1997-09-30 | Access Pharmaceuticals, Inc. | Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans |
| CA2061567C (en) * | 1992-02-20 | 1998-02-03 | Rudolf E. Falk | Use of hyaluronic acid to repair ischemia reperfusion damage |
| KR100267604B1 (en) * | 1993-06-04 | 2000-11-01 | 이 세갈 폴 | Plasma-like solution |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| DE10262084B4 (en) | 2002-05-17 | 2009-12-24 | Dr. Franz Köhler Chemie GmbH | Protective solution for the prevention of ischemic damage |
| WO2010147621A1 (en) * | 2009-06-16 | 2010-12-23 | The Trustees Of Columbia University In The City Of New York | Methods for ameliorating adverse effects associated with transfusion of aged red blood cells |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900780A (en) * | 1988-05-25 | 1990-02-13 | Masonic Medical Research Laboratory | Acellular resuscitative fluid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684482A (en) * | 1984-01-26 | 1987-08-04 | Oral-D (L.P.) | Orally effective ion chelators |
| US4863964A (en) * | 1985-07-02 | 1989-09-05 | Biomedical Frontiers, Inc. | Method for the stabilization of deferoxamine to chelate free ions in physiological fluid |
-
1990
- 1990-03-30 EP EP19900907852 patent/EP0523037A4/en not_active Withdrawn
- 1990-03-30 WO PCT/US1990/001768 patent/WO1991015215A1/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900780A (en) * | 1988-05-25 | 1990-02-13 | Masonic Medical Research Laboratory | Acellular resuscitative fluid |
Non-Patent Citations (4)
| Title |
|---|
| See also references of WO9115215A1 * |
| STN FILE SERVER & FILE BIOSIS (KARLSRUHE) 'BA86:127737' * |
| STN FILE SERVER & FILE BIOSIS (KARLSRUHE) 'BA89:41083' * |
| STN FILE SERVER & FILE BIOSIS (KARLSRUHE) 'BR38:88128' * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0523037A1 (en) | 1993-01-20 |
| WO1991015215A1 (en) | 1991-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| James | Methodology for the control of intracranial pressure with hypertonic mannitol | |
| JP5242877B2 (en) | Administration of thiol-based chemical protectants | |
| Ahrns | Trends in burn resuscitation: shifting the focus from fluids to adequate endpoint monitoring, edema control, and adjuvant therapies | |
| Matsuda et al. | Reduced fluid volume requirement for resuscitation of third-degree burns with high-dose vitamin C | |
| Mahoney et al. | Acute iron poisoning. Rescue with macromolecular chelators. | |
| US6020308A (en) | Methods for improving therapeutic effectiveness of treatment of vascularization disorders | |
| KR0156597B1 (en) | Method and composition for ameliorating tissue damage due to ischemia and reperfusion | |
| JPS6259222A (en) | Method of lowering fibrinolysis and solution therefor | |
| Sheridan et al. | Low-dose inhaled nitric oxide in acutely burned children with profound respiratory failure | |
| Sigurdsson | Intensive care management of acute pancreatitis | |
| US5416078A (en) | Fluid resuscitation | |
| EP0523037A4 (en) | Fluid resuscitation | |
| Weatherall | The pharmacological actions of some contrast media and a comparison of their merits | |
| JPS61502821A (en) | drug kit or drug composition | |
| KR102008826B1 (en) | Pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis comprising nattokinase and anti-inflammatory agents | |
| AU654652B2 (en) | Fluid resuscitation | |
| JP2000026300A (en) | Pharmaceutical composition for protecting vascular endothelial cell | |
| Russell Jr et al. | An evaluation of infusion therapy (including dextran) for venous thrombosis | |
| Fine et al. | Traumatic shock. VIII. Studies in the therapy and hemodynamics of tourniquet shock | |
| Seltzer et al. | Decrease in arterial pressure following heparin injection prior to cardiopulmonary bypass | |
| JPH11514326A (en) | Liquid resuscitation medicine | |
| Lauret et al. | Vegetating iodides after an intravenous pyelogram | |
| Pascual et al. | Blood pressure after three different forms of correction of anemia in hemodialysis | |
| Dundee et al. | Effect of thiopentone on blood sugar and glucose tolerance | |
| Bloomfield et al. | A prospective trial of diaspirin cross-linked hemoglobin solution in patients after elective repair of abdominal aortic aneurysm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19921028 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19930609 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
| DA4 | Supplementary search report drawn up and despatched (deleted) | ||
| RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 19940117 |
|
| RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 19940118 |
|
| 17Q | First examination report despatched |
Effective date: 19940727 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19990427 |